Labopharm greenshoe exercised, lifts stock sale to $101.2 million

By Lisa Kerner

Erie, Pa., May 3 - Labopharm Inc. said the underwriters of its public offering of shares exercised the 1.65 million share over-allotment option in full, raising the size of the deal to 12.65 million shares for $101.2 million.

Labopharm originally fixed the terms of the offering at $8.00 per share on April 27.

Net proceeds from the sale are $93.3 million.

Merrill Lynch & Co. and Banc of America Securities LLC acted as joint lead managing bookrunners and were joined by Canaccord Capital Corp., Leerink Swann & Co., Orion Securities Inc., Dundee Securities Corp. and Westwind Partners Inc.

Laval, Quebec-based Labopharm is a specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.